Frontiers in Cardiovascular Medicine (Oct 2019)

Complications Following Percutaneous Mitral Valve Repair

  • Livia Gheorghe,
  • Alfonso Ielasi,
  • Benno J. W. M. Rensing,
  • Frank D. Eefting,
  • Leo Timmers,
  • Azeem Latib,
  • Martin J. Swaans

DOI
https://doi.org/10.3389/fcvm.2019.00146
Journal volume & issue
Vol. 6

Abstract

Read online

Mitral valve disease affects more than 4 million people in the United States and it is the second most prevalent valvulopathy in Europe. The gold standard of treatment in these patients is surgical repair or mitral valve replacement. In the last decade, numerous transcatheter therapies have been developed to overcome the increased number of subjects with symptomatic severe mitral regurgitation and high surgical risk. The Mitraclip (Abbott Vascular, Menlo Park, CA), PASCAL (Edwards Lifesciences, Irvine, CA, USA), the Carillon™ Mitral Contour System™ (Cardiac Dimension Inc., Kirkland, WA, USA), the Mitralign™ (Mitralign, Tewksbury, Massachusetts), and the Cardioband (Edwards Lifesciences, Irvine, CA) are the principal percutaneous devices for mitral valve repair. We present an evidence-based clinical update that provides an overview of these technologies and their potential complications.

Keywords